Protocol I1V-MC-EIAN Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition with Evacetrapib in Patients at a High-Risk for Vascular Outcomes - the ACCELERATE Study

Trial Profile

Protocol I1V-MC-EIAN Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition with Evacetrapib in Patients at a High-Risk for Vascular Outcomes - the ACCELERATE Study

Discontinued
Phase of Trial: Phase III

Latest Information Update: 15 Nov 2017

At a glance

  • Drugs Evacetrapib (Primary)
  • Indications Cardiovascular disorders
  • Focus Registrational; Therapeutic Use
  • Acronyms ACCELERATE
  • Sponsors Eli Lilly
  • Most Recent Events

    • 15 Nov 2017 Results presented at the 90th Annual Scientific Sessions of the American Heart Association
    • 15 Nov 2017 Results assessing association of baseline fasting triglyceride or remnant cholesterol levels to the primary endpoint presented at the 90th Annual Scientific Sessions of the American Heart Association
    • 15 Nov 2017 Results evaluating the impact of glycemic control on the composite end point of CV death, non-fatal myocardial infarction, non-fatal stroke, hospitalization for unstable angina and revascularization in patients with established DM treated with statin presented at the 90th Annual Scientific Sessions of the American Heart Association
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top